According to Lonza, CPRI’s high-quality, small-scale services complement Lonza's extensive capabilities in custom cGMP peptide manufacturing and development. In addition, CPRI is located in North America, giving Lonza better access to the market. Lonza's existing facilities are located in: Braine-l'Alleud, Belgium, Visp, Switzerland; Nansha, China; and Kouřim, Czech Republic.
CPRI’s offering includes milligram- to multi-gram-scale custom synthesis and a wide variety of catalogue products, as well as consulting services and technical support. The alliance will provide customers a more complete peptide offering, from research through commercial supply, and enable a seamless transition of custom peptide projects between CPRI’s small-scale facility and Lonza’s cGMP facilities. Perhaps the partnership will result in the development of new and interesting peptides for the personal care industry.